Clinical Trial Detail

NCT ID NCT02644967
Title A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Idera Pharmaceuticals, Inc.
Indications

melanoma

Therapies

IMO-2125 + Ipilimumab

IMO-2125 + Pembrolizumab

Age Groups: adult

No variant requirements are available.